166 related articles for article (PubMed ID: 27504936)
1. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
[TBL] [Abstract][Full Text] [Related]
2. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new Syk inhibitors through structure-based virtual screening.
Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors.
Lee SJ; Choi JS; Bong SM; Hwang HJ; Lee J; Song HJ; Lee J; Kim JH; Koh JS; Lee BI
Mol Cells; 2018 Jun; 41(6):545-552. PubMed ID: 29890824
[TBL] [Abstract][Full Text] [Related]
5. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
[TBL] [Abstract][Full Text] [Related]
6. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Grimster NP; Gingipalli L; Barlaam B; Su Q; Zheng X; Watson D; Wang H; Simpson I; Pike A; Balazs A; Boiko S; Ikeda TP; Impastato AC; Jones NH; Kawatkar S; Kemmitt P; Lamont S; Patel J; Read J; Sarkar U; Sha L; Tomlinson RC; Wang H; Wilson DM; Zehnder TE; Wang L; Wang P; Goldberg FW; Shao W; Fawell S; Dry H; Dowling JE; Edmondson SD
Bioorg Med Chem Lett; 2020 Oct; 30(19):127433. PubMed ID: 32717371
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Barker MD; Liddle J; Atkinson FL; Wilson DM; Dickson MC; Ramirez-Molina C; Lewis H; Davis RP; Somers DO; Neu M; Jones E; Watson R
Bioorg Med Chem Lett; 2018 Nov; 28(21):3458-3462. PubMed ID: 30249354
[TBL] [Abstract][Full Text] [Related]
9. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
10. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
11. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
12. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Kawatkar SP; Barlaam B; Kemmitt P; Simpson I; Watson D; Wang P; Lamont S; Su Q; Boiko S; Ikeda T; Patel J; Pike A; Pollard H; Read J; Sarkar U; Wang H; Wen Q; Yan Z; Dowling JE; Dry H; Edmondson SD
Bioorg Med Chem Lett; 2020 Sep; 30(18):127393. PubMed ID: 32721854
[TBL] [Abstract][Full Text] [Related]
14. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study.
Wang X; Guo J; Ning Z; Wu X
Molecules; 2018 Nov; 23(12):. PubMed ID: 30487406
[TBL] [Abstract][Full Text] [Related]
17. Rational design of highly selective spleen tyrosine kinase inhibitors.
Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C
J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054
[TBL] [Abstract][Full Text] [Related]
18. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
19. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
20. Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor.
Wang C; Wang X; Li Y; Wang T; Huang Z; Qin Z; Yang S; Xiang R; Fan Y
Bioorg Chem; 2020 Jan; 95():103547. PubMed ID: 31911307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
